Skip to content
ETopical – Lifestyle
Author:
Akeso, Inc.
Akeso’s Gumokimab (IL-17A) Receives NMPA Approval for Active Ankylosing Spondylitis
November 16, 2026
Phase II Study of Ivonescimab in the Perioperative Setting for Resectable NSCLC Published in Nature Medicine
November 5, 2026
Ivonescimab Receives NMPA Priority Review for First-Line Biliary Tract Cancer
November 4, 2026
Positive Overall Survival Results from the Phase III HARMONi-GI1 Trial of Ivonescimab Plus Chemotherapy Versus Durvalumab Plus Chemotherapy in First-Line Biliary Tract Cancer Presented at the ESMO 2026 Presidential Symposium
October 25, 2026
Akeso Announces Summit Therapeutics and ECOG-ACRIN Cancer Research Group Enter into Phase II/III Clinical Trial Collaboration to Evaluate Ivonescimab in First-Line Biliary Tract Cancer
October 21, 2026
Akeso Announces Opening of Global Phase II Study of Ivonescimab in First-Line Clear Cell Renal Cell Carcinoma, Including Combination with Cadonilimab
October 19, 2026
First Patient Dosed in Phase III Perioperative Study of Cadonilimab (PD-1/CTLA-4) in Colon Cancer
October 10, 2026
Akeso Announces First Patient Enrolled in Global Phase III Trial of Cadonilimab Versus Nivolumab in First-Line Gastric Cancer
September 27, 2026
Ivonescimab First-Line Biliary Tract Cancer Phase III Overall Survival Data Selected as ESMO Late-Breaking Abstract; Nearly 30 Akeso Studies to Be Presented at ESMO 2026
September 22, 2026
Akeso’s EGFR/TROP2 Bispecific ADC AK158D1 Granted NMPA Phase I Clearance for Advanced Solid Tumors, Marking Its Fourth Clinical-Stage ADC Candidate
September 17, 2026
1
2
3
Next Page
→